“Some clinicians know about the JAK inhibitors, but it’s new to many,” said John O’Shea, MD. “The first member of this class, tofacitinib, was approved in 2012, but it’s a very fast-moving field with multiple new agents being studied.”

Everything about the way you practice rheumatology changes on Jan. 1, 2017. “We will have to re-evaluate the practice of rheumatology to adapt to upcoming changes in our compensation,” said Douglas Graham, MD.

Noah Wolcott Palm, PhD, Assistant Professor of Immunobiology and a member of the Human and Translational Immunology Program at Yale University School of Medicine, said that a large amount of microbiota-profiling data has been accumulated in the six years that microbiome sessions have been held at the Annual Meeting.

Luke O’Neill, PhD, will explore the converging worlds of inflammation and metabolism during a State-of-the-Art Lecture on Immuno-Metabolism: Energetics and Inflammation.

Not recognizing a patient’s self-identity can create communication barriers that clinicians may not even realize exist. Barbara Snyder, MD, will kick off a special symposium on gender and sexuality issues in medicine.

Activity disruption — doing things differently or not at all — is an important indicator of disease status, according to Catherine L. Backman, PhD, who will deliver this year’s ARHP Distinguished Lecture.

Ingrid Möller, MD, PhD, will describe relevant structures in the anterior hip that may generate pain during a Sunday morning symposium that’s part of the new series of “Anatomy for the Clinician.”

Multiple labs have uncovered regulatory B cells, with the subset that secretes IL-10, dubbed B10 cells by the lab led by Thomas F. Tedder, PhD.

When Arthur Weiss, MD, PhD, began investigating T cells in the 1980s, the mechanisms by which they functioned and malfunctioned were little more than a black box. The only thing that was clear was that something interacted with cells to affect genes that had something to do with growth factors, cytokines, and lymphokines to produce…